PE20211804A1 - Compuestos que aumentan la actividad del proteosoma - Google Patents
Compuestos que aumentan la actividad del proteosomaInfo
- Publication number
- PE20211804A1 PE20211804A1 PE2020002159A PE2020002159A PE20211804A1 PE 20211804 A1 PE20211804 A1 PE 20211804A1 PE 2020002159 A PE2020002159 A PE 2020002159A PE 2020002159 A PE2020002159 A PE 2020002159A PE 20211804 A1 PE20211804 A1 PE 20211804A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- alkyl
- activity
- increase
- options
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 abstract 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta referido a compuestos de Formula Ib, en donde: R1 y R2 son H, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo; R3b y R3c son H, alquilo, N3, ORc, NRdRd, C(O)ORc, NO2, CN, entre otras opciones; R4 es H, alquilo, C(O)Rc, C(O)C(O)Rc, C(O)NRdRd, entre otras opciones; R5 es H, alquilo, alquenilo, arilo, halo, entre otras opciones; Z es un N-heterociclico puenteado de 6 a 12 miembros opcionalmente sustituido. Estos compuestos aumentan la actividad del proteosoma y se emplean para el tratamiento de un cancer o un tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690565P | 2018-06-27 | 2018-06-27 | |
US201862690563P | 2018-06-27 | 2018-06-27 | |
PCT/US2019/039600 WO2020006296A1 (en) | 2018-06-27 | 2019-06-27 | Proteasome activity enhancing compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211804A1 true PE20211804A1 (es) | 2021-09-14 |
Family
ID=67439356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020002159A PE20211804A1 (es) | 2018-06-27 | 2019-06-27 | Compuestos que aumentan la actividad del proteosoma |
Country Status (16)
Country | Link |
---|---|
US (2) | US11560385B2 (es) |
EP (1) | EP3814338A1 (es) |
JP (1) | JP2021529792A (es) |
KR (1) | KR20210024588A (es) |
CN (1) | CN112585132A (es) |
BR (2) | BR122023023216A2 (es) |
CA (1) | CA3103954A1 (es) |
CL (1) | CL2020003380A1 (es) |
CR (1) | CR20200652A (es) |
IL (1) | IL279698A (es) |
MA (1) | MA53014A (es) |
MX (1) | MX2020014082A (es) |
PE (1) | PE20211804A1 (es) |
PH (1) | PH12020552261A1 (es) |
SG (1) | SG11202013026WA (es) |
WO (1) | WO2020006296A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3814348T1 (sl) | 2018-06-27 | 2023-10-30 | Bristol-Myers Squibb Company | Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic |
HRP20240401T1 (hr) | 2018-10-05 | 2024-06-07 | Annapurna Bio Inc. | Spojevi i pripravci za liječenje patoloških stanja koja su povezana s djelovanjem apj receptora |
CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
CN112142642B (zh) * | 2020-10-15 | 2022-03-04 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
WO2023107597A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Bicyclic heteroaromatic amide compounds and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1142508A (en) | 1966-04-27 | 1969-02-12 | Whitefin Holding Sa | Pyrrole derivatives |
GB1154742A (en) | 1966-05-17 | 1969-06-11 | Whitefin Holding Sa | Pyrrylamino Ketones |
AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
AU2337499A (en) | 1998-01-23 | 1999-08-09 | National Jewish Medical And Research Center | Method for treating inflammatory diseases using heat shock proteins |
US7842470B2 (en) | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
US20060148767A1 (en) | 2001-12-06 | 2006-07-06 | George Cioca | Use of acyl salicylates as heat shock inducers |
AU2004289328B2 (en) | 2003-11-12 | 2011-05-19 | Amicus Therapeutics, Inc. | Hydroxy piperidine derivatives to treat Gaucher disease |
EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
EP1888068B1 (en) | 2005-06-08 | 2014-05-21 | Amicus Therapeutics, Inc. | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
WO2007098229A2 (en) | 2006-02-21 | 2007-08-30 | Michigan State University | Geldanamycin derivatives and method of use thereof |
WO2007131034A1 (en) | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
ES2709445T3 (es) | 2006-05-16 | 2019-04-16 | Amicus Therapeutics Inc | Opciones de tratamiento para la enfermedad de Fabry |
MX2007006175A (es) | 2006-05-24 | 2009-02-16 | Amicus Therapeutics Inc | Sal de tartrato de isofagomina y metodos de uso. |
DK2040548T3 (da) | 2006-06-23 | 2012-08-13 | Amicus Therapeutics Inc | Fremgangsmåde til behandling af neurologiske forstyrrelser ved forøgelse af aktiviteten af beta-glucocerebrosidase |
WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
JP2013518129A (ja) * | 2010-01-28 | 2013-05-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | プロテアソーム活性を向上させるための組成物および方法 |
SI2707101T1 (sl) * | 2011-05-12 | 2019-06-28 | Proteostasis Therapeutics, Inc. | Regulatorji proteostaze |
US9849135B2 (en) * | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
WO2014203150A1 (en) | 2013-06-17 | 2014-12-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015073528A1 (en) * | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
-
2019
- 2019-06-27 CR CR20200652A patent/CR20200652A/es unknown
- 2019-06-27 JP JP2020573524A patent/JP2021529792A/ja active Pending
- 2019-06-27 MA MA053014A patent/MA53014A/fr unknown
- 2019-06-27 CA CA3103954A patent/CA3103954A1/en active Pending
- 2019-06-27 BR BR122023023216-0A patent/BR122023023216A2/pt unknown
- 2019-06-27 KR KR1020217002233A patent/KR20210024588A/ko unknown
- 2019-06-27 PE PE2020002159A patent/PE20211804A1/es unknown
- 2019-06-27 SG SG11202013026WA patent/SG11202013026WA/en unknown
- 2019-06-27 MX MX2020014082A patent/MX2020014082A/es unknown
- 2019-06-27 CN CN201980055152.2A patent/CN112585132A/zh active Pending
- 2019-06-27 EP EP19744945.7A patent/EP3814338A1/en active Pending
- 2019-06-27 BR BR112020026580-2A patent/BR112020026580A2/pt unknown
- 2019-06-27 WO PCT/US2019/039600 patent/WO2020006296A1/en active Application Filing
-
2020
- 2020-12-23 CL CL2020003380A patent/CL2020003380A1/es unknown
- 2020-12-23 PH PH12020552261A patent/PH12020552261A1/en unknown
- 2020-12-23 IL IL279698A patent/IL279698A/en unknown
- 2020-12-23 US US17/133,372 patent/US11560385B2/en active Active
-
2022
- 2022-11-18 US US18/057,020 patent/US20230183256A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020014082A (es) | 2021-04-13 |
CL2020003380A1 (es) | 2021-05-14 |
WO2020006296A1 (en) | 2020-01-02 |
IL279698A (en) | 2021-03-01 |
KR20210024588A (ko) | 2021-03-05 |
US20230183256A1 (en) | 2023-06-15 |
BR112020026580A2 (pt) | 2021-03-23 |
CR20200652A (es) | 2021-04-28 |
US11560385B2 (en) | 2023-01-24 |
AU2019295765A1 (en) | 2021-01-21 |
CN112585132A (zh) | 2021-03-30 |
BR122023023216A2 (pt) | 2024-02-20 |
SG11202013026WA (en) | 2021-01-28 |
CA3103954A1 (en) | 2020-01-02 |
MA53014A (fr) | 2021-05-05 |
PH12020552261A1 (en) | 2021-08-02 |
US20210115057A1 (en) | 2021-04-22 |
EP3814338A1 (en) | 2021-05-05 |
JP2021529792A (ja) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211804A1 (es) | Compuestos que aumentan la actividad del proteosoma | |
ECSP22046699A (es) | Inhibidores de kras g12c | |
CO2019012271A2 (es) | Péptido activador de receptor de gip | |
CY1124790T1 (el) | Ενωση πεπτιδιου | |
CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
PE20191461A1 (es) | Compuestos amida para el tratamiento del vih | |
CO2018002061A2 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
PE20180327A1 (es) | Proceso para preparar 4-amino-piridazinas | |
PE20211698A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
EA201791094A1 (ru) | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки | |
CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
EA201790896A1 (ru) | Пролекарства фенольных агонистов trpv1 | |
ECSP21040278A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
PE20190376A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
ECSP21013743A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CU20160148A7 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2 | |
CL2020002217A1 (es) | Uso de alcoxipirazoles como inhibidores de la nitrificación | |
CO2022000084A2 (es) | Compuestos para tratar enfermedad respiratoria | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
UY37166A (es) | Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano |